Medications for Hidradenitis Suppurativa

9 results

  • Abrilada (adalimumab-afzb)

    (adalimumab-afzb)
    Pfizer Laboratories Div Pfizer Inc
    Usage: ABRILADA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients 2 years and older.

  • Adalimumab (adalimumab)

    (adalimumab)
    Golden State Medical Supply, Inc.
    Usage: Adalimumab-fkjp is indicated for various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It reduces symptoms, inhibits structural damage progression, and improves physical function in affected patients.

  • Amjevita

    (adalimumab-atto)
    Amgen Inc
    Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

  • Amjevita (adalimumab-atto)

    (adalimumab-atto)
    Optum Health Solutions (Ireland) Limited
    Usage: AMJEVITA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It can be used alone or with other therapies.

  • Cosentyx

    (secukinumab)
    Novartis Pharmaceuticals Corporation
    Usage: COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 2 years and older, active ankylosing spondylitis in adults, active non-radiographic axial spondyloarthritis in adults, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.

  • Cyltezo

    (adalimumab-adbm)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

  • Hadlima

    (adalimumab-bwwd)
    Organon LLC
    Usage: HADLIMA is indicated for various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It alleviates symptoms, improves function, and may inhibit disease progression, used alone or with other treatments.

  • Hulio

    (adalimumab-fkjp)
    Mylan Specialty L.P.
    Usage: HULIO is indicated for reducing signs and symptoms, and improving function in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and children over 2 years.

  • Yusimry

    (adalimumab-aqvh)
    Coherus BioSciences Inc
    Usage: YUSIMRY is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It helps reduce symptoms, improve function, and inhibit structural damage in these conditions.